Inovio Pharmaceuticals (NASDAQ:INO) Shares Down 5.7%

Inovio Pharmaceuticals Inc (NASDAQ:INO) dropped 5.7% on Tuesday . The stock traded as low as $3.60 and last traded at $3.74, approximately 9,618,863 shares traded hands during trading. A decline of 2% from the average daily volume of 9,818,542 shares. The stock had previously closed at $3.96.

Several analysts recently weighed in on INO shares. Roth Capital started coverage on Inovio Pharmaceuticals in a report on Thursday, December 19th. They set a “buy” rating and a $13.00 price target on the stock. Royal Bank of Canada restated a “buy” rating and issued a $7.00 price target on shares of Inovio Pharmaceuticals in a research report on Thursday, January 23rd. ValuEngine lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Monday, January 6th. Finally, BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 18th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $7.27.

The firm has a market cap of $379.60 million, a PE ratio of -3.14 and a beta of 2.15. The company has a 50-day simple moving average of $3.71 and a 200-day simple moving average of $2.78. The company has a debt-to-equity ratio of 2.52, a current ratio of 5.06 and a quick ratio of 5.06.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim acquired 22,500 shares of the business’s stock in a transaction on Monday, January 13th. The shares were bought at an average price of $3.11 per share, with a total value of $69,975.00. Following the transaction, the chief executive officer now directly owns 1,100,707 shares of the company’s stock, valued at approximately $3,423,198.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. S.A. Mason LLC bought a new position in Inovio Pharmaceuticals in the fourth quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth $37,000. Cubist Systematic Strategies LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth $41,000. Levin Capital Strategies L.P. bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $49,000. Finally, Bank of Montreal Can raised its position in Inovio Pharmaceuticals by 29.8% during the 4th quarter. Bank of Montreal Can now owns 17,045 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 3,912 shares in the last quarter. 47.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: What are no-load funds?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.